道彤投资
@author-1784793658606
以生命科学为根，向硬科技生长
Articles
Riding the Wind, Breaking Boundaries — Tides Surge in Hong Kong | Dalton Venture 2025 CEO Summit Successfully Concludes
At the intersection of technological revolution and industrial transformation, what should be the starting point for the globalization of the life sciences industry? Where should mainland Chinese healthcare innovators set their first foothold for overseas expansion? Against a backdrop of intensifying international competition and sustained policy tailwinds, is Hong Kong — a city that blends international perspective with institutional advantages — emerging as the bridge for tech ventures to reach the world?
Heyuan Medical Closes Funding Round Exceeding RMB 100 Million, Dalton Venture Co-Leads Investment, Multiple Breakthrough Technologies Empower Heart Failure Management | Dalton Venture News
Recently, **Shanghai-based United InnoMed® announced the completion of a new funding round exceeding 100 million RMB**. The round was **jointly led by Dalton Venture and Dragonstone Capital**, with follow-on investments from Yinglian Health Fund and Tianrui Fengnian Capital. Existing investor Lilly Asia Ventures continued to increase its stake. **The proceeds will be primarily used for the R&D and registration clinical trials of multiple core pipeline products.**
Yuantian Biotechnology Closes Nearly 100 Million Yuan Pre-A+ Round, Dalton Venture Bets on Enzymatic PET Recycling | Dalton News
Recently, **Yuantian Biotechnology (Tianjin) Co., Ltd. (hereinafter referred to as "Yuantian Bio") announced the completion of a nearly 100 million yuan Pre-A+ funding round, with Dalton Venture participating in this round** to support the company's kiloton-scale production line construction, product technology advancement, and market expansion.
Dalton Venture's Sun Qi: Building Confidence Through Cyclical Swings, Riding Out Industry Ups and Downs | Dalton Insights
As winter fades and spring arrives, China's venture capital industry's annual opening gala convened as scheduled. On February 28, 2025, the "PEDaily 100" hosted by Zero2IPO and PEDaily took place in Sanya, bringing together the investment community to take the pulse of an unprecedented 2025. **Dalton Venture founding managing partner Sam Gao** was invited to participate in the roundtable discussion ***Healthcare Investment: Against the Current***, sharing Dalton Venture's positioning and thinking in the healthcare sector.
Celebrating Her Power, Gentle Shoulders Bearing Mountains and Rivers | Happy International Women's Day to the Goddesses of Entrepreneurship!
Her power knows no bounds.
Into the Dalton Family | Biolid: Where Seeds Can Be "Tailor-Made"
A pile of seeds sits before you — which ones will sprout fastest? Which will yield the most? Which will have the best quality? Traditional breeding requires months of careful observation in the field, taking at least three months of "looking, smelling, asking, and examining" to find answers. But at Shijiazhuang Biolid Biotechnology, it takes just 7 to 14 days. How is this possible? Welcome to **Dalton Venture Family company Biolid**, as we explore how Biolid spent eight years breaking foreign technology monopolies to successfully develop liquid-phase chip detection technology, dramatically shortening seed [text cuts off]
Inside Dalton Venture's Portfolio | As Medical AI Surges, Deepwise Health Moves First on a Trillion-Yuan Emerging Market
Deepwise's development has witnessed every major milestone in China's medical AI industry.
Rayton Bio Secures Dalton Venture Angel Round, Continues Leading Innovation in Long-Acting Sustained-Release Ocular Drug Delivery | Dalton News
Recently, **Shenzhen Ruitong Biomedical Co., Ltd.** (hereinafter referred to as "Ruitong Biomedical") **announced the completion of a tens-of-millions-of-yuan angel funding round**. This round was jointly invested by Dalton Venture, Qinzhi Capital, the National High-Performance Medical Device Innovation Center, and JenKem Technology (688356.SH). **The proceeds will be used to advance the company's core pipeline clinical trials and accelerate the technical development and pipeline expansion of its iSus® sustained-release platform**.
Steadfast Progress, Grounded in Action | Dalton Venture's 2024 Year in Review
Looking back at 2024, "adjustment" and "patience" became the defining keywords for venture capital. Yet on the long-distance track of life sciences and medtech, Dalton Venture kept moving forward with steady, deliberate strides. We navigated market fluctuations, caught glimpses of innovation, and helped companies take root and grow through the cycles — writing a new chapter of innovation-driven development with the power of capital.
Xiwi Microorganism Completes Nearly 100 Million Yuan Series A Funding Round Led by Dalton Venture, Building an Innovative Ophthalmic Biology and Polymer Materials Platform | Dalton Venture News
Recently, **Xiwei (Suzhou) Biomedical Technology Co., Ltd.** (hereinafter referred to as "Xiwei Biotech") **announced the completion of a nearly RMB 100 million Series A funding round, led by Dalton Venture**. The proceeds will be used to accelerate the development of its pipeline of ophthalmic and regenerative medicine innovations — including artificial biomimetic corneas, implantable contact lenses, artificial corneal endothelium sheets, and artificial dermis — as well as clinical trials, international regulatory registration, and marketing expansion.